The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade
Open accessAbstract
Introduction Proinflammatory cytokine interleukin-17A (IL-17A) is overexpressed in a subset of patients with lung cancer. We hypothesized that IL-17A promotes a protumorigenic inflammatory phenotype and inhibits antitumor immune responses. Methods We generated bitransgenic mice expressing a conditional IL-17A allele along with conditional Kras G12D and performed immune phenotyping of mouse lungs, a survival analysis, and treatment studies with antibodies either blocking programmed cell death 1 (PD-1) or IL-6 or depleting neutrophils. To support the preclinical findings, we analyzed human gene expression data sets and immune profiled patient lung tumors. Results Tumors in IL-17:Kras G12D mice grew more rapidly, resulting in a significantly shorter survival as compared with that of Kras G12D mice. IL-6, granulocyte colony-stimulating factor (G-CSF), milk fat globule-EGF factor 8 protein, and C-X-C motif chemokine ligand 1 were increased in the lungs of IL17:Kras mice. Time course analysis revealed that levels of tumor-associated neutrophils were significantly increased, and lymphocyte recruitment was significantly reduced in IL17:Kras G12D mice as compared with in Kras G12D mice. In therapeutic studies PD-1 blockade was not effective in treating IL-17:Kras G12D tumors. In contrast, blocking IL-6 or depleting neutrophils with an anti–Ly-6G antibody in the IL17:Kras G12D tumors resulted in a clinical response associated with T-cell activation. In tumors from patients with lung cancer with KRAS mutation we found a correlation between higher levels of IL-17A and colony- stimulating factor 3 and a significant correlation among high neutrophil and lower T-cell numbers. Conclusions Here we have shown that an increase in a single cytokine, IL-17A, without additional mutations can promote lung cancer growth by promoting inflammation, which contributes to resistance to PD-1 blockade and sensitizes tumors to cytokine and neutrophil depletion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“Response to PD-1 checkpoint blockade has been shown to be associated with PD-L1 expression, PD-1– positive T-cell counts, or T-cell presence in the tumor tissue.(52) By studying another mouse lung tumor model, Kras:Lkb1, we showed that Lkb1 inactivation modulates the lung immune phenotype and promotes resistance to ch…”
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
PD-L1 expression as a predictive biomarker in cancer immunotherapy
Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291
IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis
Coffelt, S. B., Kersten, K., Doornebal, C. W., Weiden, J., Vrijland, K., Hau, C.-S., Verstegen, N. J. M., Ciampricotti, M., Hawinkels, L. J. A. C., Jonkers, J., et al. (2015) · Nature · doi:10.1038/nature14282 · Cited by 1,703
Koyama, S., Akbay, E. A., Li, Y. Y., Herter-Sprie, G. S., Buczkowski, K. A., Richards, W. G., Gandhi, L., Redig, A. J., Rodig, S. J., Asahina, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms10501 · Cited by 1,580
Self-citationTargeting IL-17 and TH17 cells in chronic inflammation
Miossec, P., & Kolls, J. K. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3794 · Cited by 1,414 · cited 4×
“IL-17 is an early proinflammatory cytokine that is responsible for initiating the inflammatory response by inducing the production of several other cytokines in the target cells.(44) To understand how IL-17 affects the cytokine milieu in lungs, we measured the levels of cytokines with an ELISA.”
InfluentialFunctional Specialization of Interleukin-17 Family Members
Iwakura, Y., Ishigame, H., Saijo, S., & Nakae, S. (2011) · Immunity · doi:10.1016/j.immuni.2011.02.012 · Cited by 1,289
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., et al. (2015) · Nature · doi:10.1038/nature15520 · Cited by 1,201
Fisher, G. H., Wellen, S. L., Klimstra, D., Lenczowski, J. M., Tichelaar, J. W., Lizak, M. J., Whitsett, J. A., Koretsky, A., & Varmus, H. E. (2001) · Genes & Development · doi:10.1101/gad.947701 · Cited by 582 · cited 2×
“were induced after adenovirus administration, which results in fewer lung lesions than in mice in which tumors have been induced by CC10-Cre.(33,34) To characterize the role of IL-17A in Kras-mutant lung tumors, we developed a mouse model of chronic inflammation that more closely resembles human KRAS-mutant lung cance…”
Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells
Lee, H.-J., Zhuang, G., Cao, Y., Du, P., Kim, H.-J., & Settleman, J. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.019 · Cited by 555
An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy
Chung, A. S., Wu, X., Zhuang, G., Ngu, H., Kasman, I., Zhang, J., Vernes, J.-M., Jiang, Z., Meng, Y. G., Peale, F. V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3291 · Cited by 445
Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis
Ancrile, B., Lim, K.-H., & Counter, C. M. (2007) · Genes & Development · doi:10.1101/gad.1549407 · Cited by 422
T helper 17 cells play a critical pathogenic role in lung cancer
Chang, S. H., Mirabolfathinejad, S. G., Katta, H., Cumpian, A. M., Gong, L., Caetano, M. S., Moghaddam, S. J., & Dong, C. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319051111 · Cited by 326
Redundant Innate and Adaptive Sources of IL17 Production Drive Colon Tumorigenesis
Housseau, F., Wu, S., Wick, E. C., Fan, H., Wu, X., Llosa, N. J., Smith, K. N., Tam, A., Ganguly, S., Wanyiri, J. W., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0749 · Cited by 143
Cited by
Ferrara, R., Mezquita, L., Texier, M., Lahmar, J., Audigier-Valette, C., Tessonnier, L., Mazieres, J., Zalcman, G., Brosseau, S., Le Moulec, S., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3676 · Cited by 720
The dynamic lung microbiome in health and disease
Natalini, J. G., Singh, S., & Segal, L. N. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00821-x · Cited by 523
The IL-17 family in diseases: from bench to bedside
Huangfu, L., Li, R., Huang, Y., & Wang, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01620-3 · Cited by 452
Hyperprogressive disease: recognizing a novel pattern to improve patient management
Champiat, S., Ferrara, R., Massard, C., Besse, B., Marabelle, A., Soria, J.-C., & Ferté, C. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0111-2 · Cited by 362
Tumor-Associated Neutrophils in Cancer: Going Pro
Wu, L., Saxena, S., Awaji, M., & Singh, R. K. (2019) · Cancers · doi:10.3390/cancers11040564 · Cited by 337
Metadata
- Authors
- Akbay, E. A., Koyama, S., Liu, Y., Dries, R., Bufe, L. E., Silkes, M., Alam, M. M., Magee, D. M., Jones, R., Jinushi, M., Kulkarni, M., Carretero, J., Wang, X., Warner-Hatten, T., Cavanaugh, J. D., Osa, A., Kumanogoh, A., Freeman, G. J., Awad, M. M., Christiani, D. C., Bueno, R., Hammerman, P. S., Dranoff, G., & Wong, K.-K.
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2017-08
- Volume
- 12
- Issue
- 8
- Pages
- 1268-1279
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W2610919492
- Cited by
- 198
- References
- 17
- FWCI
- 7.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.